Location History:
- Alexandria, VA (US) (2010 - 2012)
- Springfield, VA (US) (2013)
Company Filing History:
Years Active: 2010-2013
Title: Vivian Takafuji: Innovator in Tumor Diagnosis and Treatment
Introduction
Vivian Takafuji is a prominent inventor based in Alexandria, VA (US). She has made significant contributions to the field of medical research, particularly in the diagnosis and treatment of tumors. With a total of 3 patents to her name, her work focuses on innovative therapies that target specific cancer mechanisms.
Latest Patents
One of her latest patents involves compositions and methods for the diagnosis and treatment of tumors. This patent is based on the observation of the cooperation between osteopontin (OPN) and matrix metalloproteinase-9 (MMP-9) in promoting the metastatic phenotype. The therapies and diagnostic assays disclosed in this patent are aimed at treating tumors that overexpress OPN, such as hepatocellular carcinoma (HCC). The methods include administering agents that reduce cellular invasion resulting from the interaction between a fragment of OPN (OPN-5kD) generated by MMP-9 cleavage and the CD44 receptor. Examples of such agents include fragments of OPN-5kD and antibodies specific for OPN-5kD. Additionally, the patent provides methods for diagnosing or prognosing a tumor by detecting the expression of OPN-5kD peptide or OPN-c mRNA in biological samples obtained from subjects.
Career Highlights
Vivian Takafuji is currently affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. Her work at this esteemed institution has allowed her to focus on groundbreaking research that has the potential to improve cancer treatment outcomes.
Collaborations
Some of her notable coworkers include Xin Wei Wang and Paul K Goldsmith. Their collaborative efforts contribute to the advancement of research in the field of oncology.
Conclusion
Vivian Takafuji's innovative work in tumor diagnosis and treatment exemplifies the impact of research on healthcare. Her patents reflect a commitment to developing effective therapies that address critical challenges in cancer treatment.